Abstract 558: Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockade
John L. Langowski(Novartis (Switzerland)), Deborah H. Charych(Lawrence Berkeley National Laboratory), Murali K. Addepalli(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Stephen K. Doberstein(Xencor (United States)), Rhoneil Pena(Nektar Therapeutics (United States)), Yolanda Kirksey(Princeton University), Ute Hoch(University of Arizona)
Cited by 2
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351